In this Issue:

Every morning we scan the headlines of the 250+ publicly traded medical technology companies so that you don’t have to!

Here are the top headlines for today:

• Baxter International reports quarterly revenues of $2.63 billion, a YoY increase of 5%
• Cardinal Health reports quarterly revenues of $2.63 billion, a YoY increase of 5%
• IDEXX Laboratories reports quarterly revenues of $998 million, a YoY increase of 4%
• Align Technology reports quarterly revenues of $979.3 million, a YoY decrease of 1.8%
• And 10 more companies reporting quarterly revenues today

In today’s issue we have 30 new press releases, here’s the breakdown by category:

Category:

• Finance: 21
• Clinical & Regulatory: 4
• Products & Patents: 1
• Leadership Updates: 2
• General Announcements: 2

Finance

Baxter International Inc. (BAX | DoD: +0.61% | YTD: +6.53% |MidCap: 18.0B)

• Profile: A global medtech leader
• Earnings: Quarterly revenues of $2.63 billion, a YoY increase of 5%
• Driver: “While today’s global macroeconomic factors are creating a greater degree of uncertainty in the market, we remain confident in our overarching trajectory. The benefits of our operating model in combination with our durable portfolio of medically essential products create a strong foundation to leverage our potential and pursue opportunities to help address our customers’ most pressing needs in the pursuit of our life-sustaining Mission,” said Brent Shafer, chair and interim chief executive officer (Full Text)

Cardinal Health, Inc. (CAH | DoD: +1.04% | YTD: +19.72% | LargeCap: 30.8B)

• Profile: A leading distributor of pharmaceuticals, a global manufacturer and distributor of medical and laboratory products, and a provider of performance and data solutions for healthcare facilities
• Earnings: Quarterly revenues of $54.9 billion, a YoY change of 0%
• Driver: Third quarter revenue increased 19% excluding the impact of the previously communicated customer contract expiration. (Full Text)

IDEXX Laboratories, Inc. (IDXX | DoD: -0.99% | YTD: +5.82% | LargeCap: 35.9B)

• Profile: A global leader in pet healthcare innovation
• Earnings: Quarterly revenues of $998 million, a YoY increase of 4%
• Driver: At the end of March, IDEXX launched a first-of-its-kind innovation, IDEXX Cancer Dx™, in our North American reference laboratories,” said Jay Mazelsky, President and Chief Executive Officer. (Full Text)

CVS Health Corporation (CVS | DoD: +2.58% | YTD: +50.86% | MidCap: 81.3B)

• Profile: A leading diversified health solutions company
• Earnings: Quarterly revenues of $94.6 billion, a YoY increase of 7%
• Driver: “As we aim to be the most trusted health care company in America, we are driving greater care, value, and service from our integrated, industry-leading businesses.” (Full Text)

Teleflex Incorporated (TFX | DoD: -0.85% | YTD: -23.46% | MIdCap: 6.5B)

• Profile: A provider of specialty medical devices for a range of procedures in critical care and surgery
• Earnings: Quarterly revenues of $700.7 million, a YoY decrease of 5.0%
• Driver: Teleflex’s Chairman, President and Chief Executive Officer. “Were it not for the impact of tariffs enacted since the issuance of our previous guidance, we project that our full-year results for 2025 would fall within our previously stated guidance ranges. We are evaluating strategies to mitigate our exposure to tariffs and remain highly focused on executing our plan for the year. (Full Text)

Becton, Dickinson and Company (BDX | DoD: +0.31% | YTD: -8.57% | LargeCap: 64.4B)

• Profile: A leading global medical technology company
• Earnings: Quarterly revenue of $5.3 billion, a YoY increase of 4.5%:
• Driver: “Our BD Excellence operating system is driving continued margin expansion and increasing investment in our commercial organization and innovation, and we believe we are well positioned to accelerate growth as markets recover. As we take decisive mitigation actions to navigate the current macro environment, BD’s scale as the largest U.S. manufacturer of medical devices is a significant advantage for long-term value creation.” (Full Text)

Align Technology, Inc. (ALGN | DoD: -2.50% | YTD: -16.88% | MidCap: 13.9B)

• Profile: A leading global medical device company that designs, manufactures, and sells the Invisalign® System of clear aligners
• Earnings: Quarterly revenues of $979.3 million, a YoY decrease of 1.8%
• Driver: Align Technology President and CEO Joe Hogan said, “I am pleased to report first quarter revenues, operating margin, and earnings in line with our outlook. Fiscal 2025 is off to a good start with Q1 Clear Aligner volumes up both sequentially and year-over-year, reflecting strength in both the teens and adult patient segments, across all regions, driven by year over year strength across the Asia Pacific and EMEA regions, and growth in North America. It is worth noting that Q1 is our highest year-over-year growth rate for both adult and teen patients since 2021.” (Full Text)

Guardant Health, Inc. (GH | DoD: -4.64% | YTD: +48.66% | MidCap: 5.2B)

• Profile: A leading precision oncology company
• Earnings: Quarterly revenues of $203.5 million, a YoY increase of 21%
• Driver: “We started the year with very strong momentum across our portfolio, fueled by ground-breaking product upgrades and new tests introduced in 2024 which leverage our smart liquid biopsy platform,” said Helmy Eltoukhy, co-founder and co-CEO. (Full Text)

Glaukos Corporation (GKOS | DoD: +0.45% | YTD: -37.03% | MidCap: 6.7B)

• Profile: An ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases
• Earnings: Quarterly revenues o f$106.7 million, a YoY increase of 25%
• Driver: Thomas Burns, Glaukos chairman and chief executive officer. “We continue to successfully advance our robust pipeline of novel, dropless platform technologies designed to meaningfully advance the standard of care and improve outcomes for patients suffering from chronic eye diseases.” (Full Text)

CONMED Corporation (CNMD | DoD: -4.03% | YTD: -27.08% | MidCap: 1.8B)

• Profile: A medical technology company that provides devices and equipment for surgical procedures
• Earnings: Quarterly revenues of $321.3 million, a YoY increase of 2.9%
• Driver: “We had a good start to 2025, which positions us well to achieve our full-year guidance,” commented Patrick J. Beyer, CONMED’s President and Chief Executive Officer. (Full Text)

Tandem Diabetes Care, Inc. (TNDM | DoD: +0.48% | YTD: -52.99% | MidCap: 1.4B)

• Profile: A leading insulin delivery and diabetes technology company
• Earnings: Quarterly revenues of $234.4 million, a YoY increase of 22%
• Driver: “The strength of our first quarter performance was driven by more than 20% worldwide sales growth, including our highest quarter ever outside the United States,” said John Sheridan, president and chief executive officer. (Full Text)

Teladoc Health, Inc. (TDOC | DoD: -1.91% | YTD: -24.47% | MidCap: 1.6B)

• Profile: The global leader in virtual care
• Earnings: Quarterly revenues of $629.4 million, a YoY decrease of 3%
• Driver: “We are pleased with the solid start to 2025. Consolidated revenue and adjusted EBITDA were towards the higher end of our first quarter guidance ranges, including our Integrated Care segment being above our ranges for both measures and BetterHelp segment results in the upper half of our ranges as well. (Full Text)

Accuray Incorporated (ARAY | DoD: -4.32% | YTD: -20.51% | SmallCap: 206M)

• Profile: A global leader in the field of radiation oncology
• Earnings: Quarterly revenues of $113.2 million, a YoY increase of 12
• Driver: “We achieved a strong third quarter and I am proud of the resiliency of the entire team and their focus on driving actions to mitigate the impact of the tariffs. (Full Text)

Pulmonx Corporation (LUNG | DoD: -8.35% | YTD: -25.92% | SmallCap: 343M)

• Profile: A global leader in minimally invasive treatments for lung disease
• Earnings: Quarterly revenues of $22.5 million, a YoY increase of 20%
• Driver: “We are off to a strong start in 2025 as we continue to advance our Acquire, Test, and Treat strategy to broaden patient access to Zephyr Valves,” said Steve Williamson, President and Chief Executive Officer. (Full Text)

enVVeno Medical Corporation (NVNO | DoD: +1.01% | YTD: -2.28% | SmallCap: 62M)

• Profile: A company setting new standards of care for the treatment of deep venous disease
• Financial Update: Cash Burn of $4.0 million in Q1 remains in line with projected quarterly range
• Driver: Robert Berman, enVVeno Medical’s Chief Executive Officer, commented “In the first quarter, we continued to present our compelling 1-year data from the U.S. pivotal trial at leading global, scientific conferences to socialize and engage directly with leading vascular surgeons as we lay the foundation for the potential phased market entry of the VenoValve, pending FDA approval. (Full Text)

DarioHealth Corp. (DRIO | DoD: -0.64% | YTD: -12.90% | SmallCap: 26M)

• Profile: A leading global digital health company
• Refinance: DarioHealth Closes Strategic Refinancing of Existing Debt Facility of up to $50 Million to Provide Additional Operational Flexibility and Support (Full Text)

McKesson Corporation (MCK | DoD: +0.78% | YTD: +25.89% | LargeCap: 77.8B)

• Profile: The leading healthcare company for wholesale medical supplies & equipment, pharmaceutical distribution, and healthcare technology solutions.
• Dividend: McKesson Corporation Declares Quarterly Dividend (Full Text)

NeoGenomics, Inc. (NEO | DoD: -2.81% | YTD: -61.22% | MidCap: 1.3B)

• Profile: A high-complexity CLIA-certified clinical laboratory, pharma services and information services company that specializes in cancer genetics diagnostic testing
• Convertible Note: NeoGenomics Pays Off 1.25% Convertible Senior Notes (Full Text)

Aspira Women’s Health Inc. (AWH | DoD: -12.5% | YTD:-88.37% | SmallCap: 3M)

• Profile: A bio-analytical based women’s health company focused on the development of gynecologic disease diagnostic tools
• Milestone: Aspira Reaches Another ARPA-H Milestone, Eligible to Receive Additional $1.5 Million in Second Quarter (Full Text)

Coloplast A/S (CLPBY | DoD: +1.17% | YTD: +5.22% | MidCap: 24.4B)

• Profile: A leading medical device company that develops, manufactures and markets products and services within Chronic Care, Interventional Urology and Wound & Skin Care
• Revised Guidance: Coloplast A/S Revised guidance for FY 2024/25, the organic growth is now expected to be around 7%, from previously 8-9%.(Full Text)

Sonendo, Inc. (SONX | DoD: +0.00% | YTD: -37.70% | SmallCap: 1M)

• Profile: A leading dental technology company and developer of the GentleWave® System
• Private Placement: Sonendo, Inc. Announces $5.0 Million Private Placement (Full Text)

Clinical & Regulatory

Edwards Lifesciences Corporation (EW | DoD: -1.04% | YTD: +4.00% | Cap: 42.1B)

• Profile: A medical technology company specializing in artificial heart valves and hemodynamic monitoring
• FDA Clearance: Edwards TAVR Receives FDA Approval for Patients With Asymptomatic Severe Aortic Stenosis (Full Text)

Castle Biosciences, Inc. (CSTL | DoD: +1.01% | YTD: -28.50% | Cap: 708M)

• Profile: A company improving health through innovative tests that guide patient care
• Clinical: New Study Shows Castle Biosciences’ DecisionDx®-Melanoma Test Outperforms Staging and CP-GEP in Identifying Patients at Low Risk of Sentinel Lymph Node Positivity (Full Text)

Spectral AI, Inc. (MDAI | DoD: +0.00% | YTD: -52.38% | Cap: 34M)

• Profile: A leading developer of the AI-driven DeepView® System, which uses multi-spectral imaging and AI algorithms to predict burn healing potential
• Clinical: Burn clinicians present positive findings of the DeepView® System’s accuracy at the American Burn Association annual meeting (Full Text)

Lantheus Holdings, Inc. (LNTH | DoD: +0.37% | YTD: +17.50% | Cap: 6.3B)

• Profile: The leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes
• Clinical: Lantheus Announces Alzheimer’s Disease Radiodiagnostic MK-6240 Meets Co-Primary Endpoints in Two Pivotal Studies (Full Text)

Products & Patents

electroCore, Inc. (ECOR | DoD: +3.30% | YTD: -56.14% | Cap: 102M)

• Profile: A commercial-stage bioelectronic medicine and wellness company
• Product: electroCore’s Truvaga™ Now Works with the Apple Health app (Full Text)

General Announcements

ICU Medical, Inc. (ICUI | DoD: -0.50% | YTD: -13.54% | Cap: 3.7B)

• Profile: A medical device company that provides infusion pumps and other products
• Partnership: ICU Medical, Inc. and Otsuka Pharmaceutical Factory, Inc. Complete Joint Venture to Bolster IV Solutions Manufacturing and Innovation in North America (Full Text)

Siemens Healthineers AG (SMMNY | DoD: +0.68% | YTD: +2.46% | Cap: 62.8B)

• Profile: Maker of diagnostic and therapeutic products and services to healthcare providers
• Presentation: More Impact, Together: Varian and Siemens Healthineers Portfolios Highlight More Impact, Innovations and More Breakthroughs Throughout Cancer Care Journey at ESTRO 2025 (Full Text)

Leadership Updates

Claritev Corporation (CTEV | DoD: -2.56% | YTD: +73.20% | Cap: 375M)

• Profile: A healthcare technology, data and insights company focused on delivering affordability, transparency and quality to the U.S. healthcare system
• Leadership Announcement: Claritev Appoints Jason Kap to its Board of Directors (Full Text)

The Cooper Companies, Inc. (COO | DoD: -0.68% | YTD: -9.92% | Cap: 17.9B)

• Profile: A leading global medical device company
• Leadership Update: CooperCompanies Appoints Barbara Carbone to Board of Directors (Full Text)

Cosmos Health Inc. (COSM | DoD: +3.49% | YTD: -38.13% | Cap: 11M)

• Profile: A diversified, vertically integrated global healthcare group engaged in innovative R&D, owner of proprietary pharmaceutical and nutraceutical brands, manufacturer and distributor of healthcare products, and operator of a telehealth platform
• Disclosure: Cosmos Health CEO Greg Siokas Acquires 1,466,764 Shares Valued at $526,000 Over the Past Week; 2,777,469 Shares Acquired Over the Past Five Months for $1,325,000 (Full Text)